

April 12, 2007

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/519,219-Conf. #7317
				Filing Date	May 13, 2005
				First Named Inventor	Venkateswarlu Jasti
				Art Unit	4843 1626
				Examiner Name	N. Grazier Stockton
Sheet	1	of	3	Attorney Docket Number	03108/0202223-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-3,481,953	12/02/1969	Herbst	
	AB	US-4,839,377	06/13/1989	Bays et al.	
	AC	US-4,855,314	08/08/1989	Oxford et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	BA	WO 02/078693	10/10/2002	Eli Lilly and Company	
	BB	EP 0 457 701	02/22/1995	Immunotech S.A.	
	BC	WO 94/06769	03/03/1994	Samjin Pharm. Co. Ltd.	
	BD	WO 93/23386	11/25/1993	Merck Sharp & Dohme Ltd.	
	BE	WO 93/00086	01/07/1993	Smith-Kline Beecham PLC	
	BF	EP 0 497 512	08/05/1992	Merck Sharp & Dohme Ltd.	
	BG	EP 0 438 230	07/24/1991	Merck Sharp & Dohme Ltd.	
	BH	WO 91/18897	12/12/1991	The Wellcome Foundation Limited	
	BI	EP 0 354 777	02/14/1990	Glaxo Group Limited	
	BJ	EP 0 313 397	06/02/1993	The Wellcome Foundation Limited	
	BK	EP 0 303 506	02/15/1989	Glaxo Group Limited	
	BL	GB 2 035 310	06/18/1980	Glaxo Group Limited	
	BM	WO 00/34242	06/15/2000	Virginia Commonwealth University	
	BN	GB 2 341 549	03/22/2000	Merck Sharp & Dohme	
	BO	JP-A 2000-026471 (ABSTRACT)	01/25/2000	Nippon Soda Co. Ltd.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Glennon, Richard A., et al., 2000, 2-Substituted Tryptamines: Agents with Selectivity for 5-HT ₆ Serotonin Receptors. <i>J. Med. Chem.</i> 43:1011-1018.	

Examiner Signature		Date Considered	5/22/07
--------------------	--	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,219-Conf. #7317
				Filing Date	May 13, 2005
				First Named Inventor	Venkateswarlu Jasti
				Art Unit	1643
				Examiner Name	N. Grazier
Sheet	2	of	3	Attorney Docket Number	03108/0202223-USO

No Copy Provided

CB	Tsai, Yuching, et al., 2000, N ₁ -(Benzenesulfonyl)tryptamines as Novel 5-HT ₅ Antagonists. <i>Bioorganic & Medicinal Chemistry Letters</i> 10:2295-2299.
CC	Boess, Frank G., et al., 1998, The 5-Hydroxytryptamine ₆ Receptor-Selective radioligand [³ H]Ro 63-0653 Labels 5-Hydroxytryptamine Receptor Binding Sites in Rat and Porcine Striatum. <i>Molecular Pharmacology</i> 54:577-583.
CD	Bourson, Anne, et al., 1998, Involvement of 5-HT ₆ receptors in nigro-striatal function in rodents. <i>British Journal of Pharmacology</i> 125:1562-1566.
CE	Sleight, Andrew J. et al., 1998, Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT ₆ receptors. <i>British Journal of Pharmacology</i> 124:556-562.
CF	Sleight, Andrew J., et al. The 5-hydroxytryptamine₆ receptor: localisation and function. Exp. Opin. Ther. Patents 8(10):1217-1224.
CG	Yoshioka, M., et al., 1998, Central Distribution and Function of 5-HT ₆ Receptor Subtype in the Rat Brain. <i>Life Sciences</i> 62(17/18):1473-1477.
CH	Hoyer, Daniel, et al., 1994, VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). <i>Pharmacological Reviews</i> 46(2):157-203.
CI	Martin, G.R. and P.P.A. Humphrey, 1994, Receptors for 5-Hydroxytryptamine: Current Perspectives on Classification and Nomenclature. <i>Neuropharmacology</i> 33(3/4):261-273.
CJ	Rees, Stephen, et al., 1994, Cloning and Characterisation of the human 5-HT _{5A} serotonin receptor. <i>FEBS Letters</i> 355(242-246).
CK	Roth, Bryan L., et al., 1994, Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine-7 Receptors. <i>The Journal of Pharmacology and Experimental Therapeutics</i> 268(3):1403-1410.
CL	Grossman, C.J., et al., 1993, Development of a radioligand binding assay for 5-HT ₄ receptors in guinea-pig and rat brain. <i>British Journal of Pharmacology</i> 109:618-624.
CM	Monsma, Jr., Frederick J., et al., 1993, Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs. <i>Molecular Pharmacology</i> 43:320-327.
CN	Ruat, Martial, et al., 1993, A Novel Rat Serotonin (5-HT ₆) Receptor: Molecular Cloning, Localization and Stimulation of Camp Accumulation. <i>Biochemical and Biophysical Research Communications</i> 193(1):268-276.
CO	Schoeffter, Philippe, et al., 1993, SDZ 216-525, a selective and potent 5-HT _{1A} receptor antagonist. <i>European Journal of Pharmacology - Molecular Pharmacology Section</i> 244:251-257.
CP	Shen, Yong, et al., 1993, Molecular Cloning and Expression of 5-Hydroxytryptamine ₇ Serotonin Receptor Subtype. <i>The Journal of Biological Chemistry</i> 268(24):18200-18204.
CQ	Spadoni, Gilberto, 1993, 2-Substituted 5-Methoxy-N-acyltryptamines: Synthesis, Binding Affinity for the Melatonin Receptor, and Evaluation of the Biological Activity. <i>J. Med. Chem.</i> 36:4068-4074.
CR	Glennon, Richard A., 1990, Serotonin Receptors: Clinical Implications. <i>Neuroscience & Biobehavioral Reviews</i> 14:35-47.
CS	Lummls, Sarah C.R., et al., 1990, Characterization of 5-HT ₃ receptors in intact N1E-115 neuroblastoma cells. <i>European Journal of Pharmacology - Molecular Pharmacology Section</i> 189:223-227.

Examiner Signature	<i>Jan S. Stettin</i>	Date Considered	5/22/07
--------------------	-----------------------	-----------------	---------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,219-Conf. #7317
				Filing Date	May 13, 2005
				First Named Inventor	Venkateswarlu Jasti
				Art Unit	4643
				Examiner Name	N. Crozier
Sheet	3	of	3	Attorney Docket Number	03108/0202223-USO

CT	Saxena, Pramod R. and Carlos M. Villalón, 1990, Cardiovascular Effects of Serotonin Agonists and Antagonists. <i>Journal of Cardiovascular Pharmacology</i> 15(7):S17-S34.
CU	Gershon, Michael D., et al., 1989, 5-Hydroxytryptamine and enteric neurones. In <i>The Peripheral Actions of 5-Hydroxytryptamine</i> . J. Fozard, editor. Oxford University Press, Oxford. 247-273
CV	Schoeffter, Philippe and Daniel Hoyer, 1989, How selective is GR 43175? Interactions with functional 5-HT _{1A} , 5-HT _{1B} , 5-HT _{1C} and 5-HT _{1D} receptors. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> 340:135-138.
CW	Waeber, C., et al., 1988, Molecular Pharmacology of 5-HT _{1D} recognition sites: Radioligand binding studies in human, pig and calf brain membranes. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> 337:595-601.
CX	Hoyer, Daniel and Hans C. Neijt, 1988, Identification of Serotonin 5-HT ₃ Recognition Sites in Membranes of N1E-115 Neuroblastoma Cells by Radioligand Binding. <i>Molecular Pharmacology</i> 33:303-309.
CY	Hoyer, Daniel, et al., 1985, Molecular Pharmacology of 5-HT ₁ and 5-HT ₂ Recognition Sites in Rat and Pig Brain Membranes: Radioligand Binding Studies with [³ H]5-HT, [³ H]8-OH-DPAT, (-)-[¹²⁵ I]iodocyanopindolol, [³ H]Mesulergine and [3H]Ketanserin. <i>European Journal of Pharmacology</i> 118:13-23.
CZ	Pazos, Angel, et al., 1985, The Binding of Serotonergic Ligands to the Porcine Choroid Plexus: Characterization of a New Type of Serotonin Recognition Site. <i>European Journal of Pharmacology</i> 106:539-546.
CA1	Fuller, R.W., 1982, Drugs Acting on Serotonergic Neuronal Systems, in <i>Biology of Serotonergic Transmission</i> . Neville N. Osborn, ed. John Wiley & Sons. Chichester. 221-247.
CB1	Leysen, J.E., et al., 1981, [³ H]Ketanserin (R 41 468), a Selective 3H-Ligand for Serotonin ₂ Receptor Binding Sites. Binding Properties, Brain Distribution, and Functional Role. <i>Molecular Pharmacology</i> 21:301-314.
CC1	Baldwin, J.E., ed. 1996, Reduction of Carbon-Carbon Bonds in Principles of Asymmetric Synthesis. 311-316.
CD1	Tyers, M.B., 1991, 5-HT ₃ receptors and the therapeutic potential of 5-HT ₃ receptor antagonists. <i>Therapie</i> . 46:431-436.
CE1	Russell M.G. et al., 2001, N-Arylsulfonylindole derivatives as serotonin 5-HT ₆ receptor ligands. <i>J. Med. Chem.</i> 44(23):3881-3895.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Ran S. Stoltz</i>	Date Considered	5/22/07
--------------------	----------------------	-----------------	---------